IRadimed Expects FY23 Revenue Of $64.5M-$65.5M Vs. Prior Guidance Of $62M-$63.5M And Consensus Of $63.09M; It Sees Adjusted EPS Of $1.37-$1.40 Vs. Previous Outlook Of $1.26-$1.35 And Consensus Of $1.30
Portfolio Pulse from Benzinga Newsdesk
IRadimed has updated its FY23 revenue guidance to $64.5M-$65.5M, up from the previous guidance of $62M-$63.5M and above the consensus of $63.09M. The company also raised its adjusted EPS forecast to $1.37-$1.40, compared to the previous outlook of $1.26-$1.35 and consensus of $1.30.
August 04, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IRadimed's updated FY23 revenue and EPS guidance exceed previous estimates and consensus, indicating a positive outlook for the company.
IRadimed's updated guidance for FY23, which exceeds previous estimates and consensus, indicates that the company is performing better than expected. This positive news is likely to increase investor confidence and could drive up the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100